ALS, MS & Neurodegenerative Diseases: Chronic Infections as Root Cause Triggers & Comprehensive Testing Panel (Part 2 of 2)

Overview: Chronic Infections as Root Cause Triggers in Neurodegeneration

This is Part 2 of 2. See Part 1 for ALS/MS pathophysiology, repurposed drugs (PrimeC, niclosamide, ivermectin, mebendazole, LDN, masitinib), iron dysregulation and ferroptosis, DMSO protocols, and BBB-crossing supplement stacks.

Chronic and reactivated infections are increasingly recognized as upstream initiators and accelerants of neurodegeneration — not merely incidental findings. They drive persistent neuroinflammation, BBB disruption, molecular mimicry, mitochondrial dysfunction, and immune exhaustion that collectively create the conditions for ALS, MS, PD, and AD to develop and progress.

Category 5: Key Pathogens and Their Neurological Mechanisms

Epstein-Barr Virus (EBV)

• MS link — landmark 2022 study (Bjornevik et al., Science, 2022) demonstrated EBV infection precedes MS diagnosis by years in virtually all cases. Risk of MS increased 32-fold after EBV infection in a military cohort of 10 million.
• Mechanism — EBV latently infects B-cells that infiltrate the CNS; molecular mimicry between EBV protein GlialCAM and myelin antigens triggers autoimmune demyelination.
• AD link — EBV DNA found in brain tissue of AD patients; EBV-driven neuroinflammation may accelerate amyloid deposition.
• Reactivation marker — elevated EA-D IgG (early antigen) indicates active reactivation, not just past exposure. This marker is often omitted from standard panels — must be specifically requested.

HSV-1 (Herpes Simplex Virus Type 1)

• AD link — HSV-1 DNA found within amyloid plaques; triggers amyloid precursor protein (APP) processing and tau phosphorylation. (Itzhaki et al., Journal of Alzheimer's Disease, 2018)
• Population data — valacyclovir associated with significantly reduced AD risk in large Taiwanese population study. (Tzeng et al., Neurotherapeutics, 2018)
• ALS relevance — HSV-1 reactivation in motor neurons documented; viral-driven TDP-43 mislocalization is a proposed mechanism.

CMV (Cytomegalovirus)

• Drives chronic T-cell exhaustion and immune senescence, reducing capacity to clear pathogens and misfolded proteins.
• Associated with accelerated cognitive decline and increased MS lesion burden in seropositive patients.
• Elevates IL-6 and TNF-α, directly accelerating neurodegeneration.
• Quantitative PCR distinguishes active replication from latent infection — critical for treatment decisions.

HHV-6 (Human Herpesvirus 6)

• HHV-6A (not HHV-6B) preferentially infects oligodendrocytes and astrocytes, directly damaging myelin-producing cells.
• HHV-6 DNA found in MS plaques at higher frequency than in normal brain tissue.
• Reactivation during immune stress may trigger MS relapses.
• Often missed on standard panels — requires quantitative PCR. Must specify HHV-6A vs. HHV-6B when ordering.

Rickettsia

• Obligate intracellular bacteria transmitted by ticks, lice, and mites. Invade endothelial cells lining the BBB.
• Cause CNS vasculitis, BBB disruption, and neuroinflammation that can mimic or accelerate MS-like demyelination.
• Rickettsia rickettsii (Rocky Mountain Spotted Fever) can cause acute encephalitis; chronic low-grade Rickettsia infection may contribute to persistent neuroinflammation.
• Often seronegative in chronic presentations — requires both IgG/IgM serology and PCR for adequate sensitivity.

Bartonella

• Increasingly linked to neuropsychiatric illness, encephalopathy, seizures, and peripheral neuropathy. Bartonella henselae has been detected in CSF of neurological patients.
• Infects endothelial cells and erythrocytes; causes chronic immune activation, elevated VEGF, and angiogenic dysregulation in the CNS.
• Strongly associated with treatment-resistant neurological and psychiatric presentations in Lyme-co-infected patients.
• Critical note — standard IgG/IgM serology misses up to 50% of Bartonella cases. Galaxy Diagnostics ePCR (enrichment PCR) is the gold standard.

Babesia

• Intraerythrocytic parasite transmitted by Ixodes ticks; co-infects with Borrelia (Lyme) in endemic areas.
• Causes hemolytic anemia, cytokine storms (IL-6, TNF-α, IL-10), and CNS hypoxia from red blood cell destruction — all accelerating neurodegeneration.
• Babesia-driven immune dysregulation impairs clearance of misfolded proteins and promotes microglial hyperactivation.
• Two primary US species: B. microti (Northeast) and B. duncani (West Coast) — both must be tested separately as standard panels often only include B. microti.

Borrelia (Lyme Neuroborreliosis)

• Borrelia spirochetes have been found in brain tissue of ALS patients in case series — neuroborreliosis may be misdiagnosed as ALS in some patients.
• Neuroborreliosis can mimic MS (white matter lesions, demyelination) and ALS (motor neuron involvement, fasciculations).
• Standard CDC 2-tier testing (ELISA + Western Blot) misses 30–50% of cases. IGeneX Western Blot is significantly more sensitive — request full band reporting.

Category 6: Comprehensive Infection Testing Panel for Neurodegeneration

A comprehensive infection workup should be considered in any patient with ALS, MS, PD, or unexplained neurological decline — particularly those with treatment-resistant presentations or a history of tick exposure, immune dysregulation, or reactivation symptoms.

Tick-Borne & Intracellular Pathogen Panel

Herpesvirus Reactivation Panel

Immune & Inflammatory Contextualization Panel

These markers help quantify the immune burden and neuroinflammatory state driven by chronic infections:

• NK cell activity (CD56/CD16 flow cytometry) — suppressed in chronic viral reactivation; indicates immune exhaustion
• CD4/CD8 ratio — inversion suggests chronic viral immune pressure
• Cytokine panel: IL-6, IL-1β, TNF-α, IL-10, TGF-β — quantifies neuroinflammatory burden
• TGF-β1 — elevated in Lyme, mold illness, and Bartonella; drives immune suppression
• C4a complement — elevated in tick-borne illness and mold/biotoxin exposure; marker of innate immune activation
• MMP-9 — elevated in Lyme neuroborreliosis and BBB disruption; marker of neuroinflammatory vascular damage
• Neurofilament Light Chain (NfL) — serum biomarker of active neuronal damage; elevated in ALS, MS, and infection-driven neurodegeneration. Useful for monitoring treatment response.
• GFAP (Glial Fibrillary Acidic Protein) — marker of astrocyte activation and CNS injury

Recommended Laboratories

• IGeneX (Palo Alto, CA) — best for Lyme, Bartonella, Babesia, Rickettsia, Ehrlichia. Comprehensive Tick-Borne Disease Panel covers most pathogens simultaneously. igenex.com
• Galaxy Diagnostics (Research Triangle Park, NC) — gold standard specifically for Bartonella ePCR + serology. galaxydx.com
• Armin Labs (Germany) — EliSpot-based T-cell testing for Borrelia, Bartonella, Babesia, EBV, CMV, HHV-6. Detects cellular immunity — catches seronegative cases that standard serology misses. Ships internationally. arminlabs.com
• Quest Diagnostics / LabCorp — adequate for herpesvirus panels (EBV full panel, CMV, HSV, HHV-6 IgG); insufficient for tick-borne pathogens.
• Vibrant America / Vibrant Wellness — comprehensive tick-borne and viral panels with good neurological sensitivity.

Suggested 3-Phase Ordering Strategy

• Phase 1 (Quest/LabCorp — start here): EBV full panel (VCA IgG/IgM, EA-D IgG, EBNA IgG, EBV PCR quantitative), CMV IgG/IgM + PCR, HSV-1/2 IgG, HHV-6 IgG + PCR, cytokine panel (IL-6, TNF-α, IL-1β), NfL serum, GFAP, MMP-9, C4a complement, TGF-β1, CD4/CD8 ratio, NK cell activity
• Phase 2 (Specialty labs — if Phase 1 immune markers suggest infection burden): IGeneX Tick-Borne Disease Panel (Lyme, Babesia microti + duncani, Bartonella, Rickettsia, Ehrlichia, Anaplasma) + Galaxy Diagnostics Bartonella ePCR
• Phase 3 (Seronegative but high clinical suspicion): Armin Labs EliSpot panel for cellular immunity to Borrelia, Bartonella, EBV, CMV — detects infection even when antibody tests are negative

Treatment Considerations for Confirmed Infections

Treatment of confirmed infections should always be directed by a qualified specialist — a Lyme-literate medical doctor (LLMD) for tick-borne pathogens, or an infectious disease physician for herpesvirus reactivation.

• EBV/HSV-1/CMV/HHV-6 reactivation — valacyclovir or famciclovir; dosing and duration per specialist guidance
• Rickettsia, Bartonella, Ehrlichia, Anaplasma — doxycycline is first-line; Bartonella often requires a 3-drug protocol including rifampin
• Babesia — atovaquone ± azithromycin; severe cases may require additional agents
• Borrelia (Lyme) — doxycycline, amoxicillin, or cefuroxime for early disease; IV ceftriaxone for neuroborreliosis per LLMD guidance
• Lactoferrin — broad-spectrum antimicrobial + iron chelation + BBB penetration; supportive across all infection categories
• LDN (Low-Dose Naltrexone) — adjunct immune modulator; reduces neuroinflammation driven by chronic infections

Important Disclaimer

The information presented in this article is for educational purposes only and does not constitute medical advice. Neurodegenerative diseases and chronic infections are serious conditions requiring individualized medical management. Infection testing and treatment protocols should only be pursued under the supervision of a qualified healthcare practitioner — ideally a neurologist, integrative medicine physician, or Lyme-literate medical doctor (LLMD). Always consult your physician before initiating any new diagnostic or treatment protocol.

← Return to Part 1: ALS, MS & Neurodegenerative Diseases — Root Causes, Repurposed Drugs, Iron Dysregulation, DMSO, and BBB-Crossing Supplements

Key References

• Bjornevik K, et al. Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis. Science. 2022;375:296–301.
• Itzhaki RF, et al. Microbes and Alzheimer's Disease. Journal of Alzheimer's Disease. 2018;51:979–984.
• Tzeng NS, et al. Anti-herpetic medications and reduced risk of dementia in patients with herpes simplex virus infections. Neurotherapeutics. 2018;15:417–429.
• Blacher E, et al. Potential roles of gut microbiome and metabolites in modulating ALS in mice. Nature. 2019;572:474–480.
• Younger J, et al. Low-dose naltrexone for the treatment of fibromyalgia. Pain Medicine. 2014;15:1–7.